Extrahepatic Bile Duct Adenocarcinoma

LAUR Repository

Show simple item record

dc.contributor.author Borghero, Yerko
dc.contributor.author Crane, Christopher
dc.contributor.author Szklaruk, Janio
dc.contributor.author Oyarzo, Mauricio
dc.contributor.author Curley, Steven
dc.contributor.author Pisters, Peter
dc.contributor.author Evans, Douglas
dc.contributor.author Abdalla, Eddie
dc.contributor.author Thomas, Melanie
dc.contributor.author Das, Prajnan
dc.contributor.author Wistuba, Ignacio
dc.contributor.author Krishnan, Sunil
dc.contributor.author Vauthey, Nicolas
dc.date.accessioned 2015-11-16T12:50:44Z
dc.date.available 2015-11-16T12:50:44Z
dc.date.copyright 2008
dc.date.issued 2015-11-16
dc.identifier.issn 1068-9265 en_US
dc.identifier.uri http://hdl.handle.net/10725/2585
dc.description.abstract Background Patients with resected extrahepatic bile duct adenocarcinoma who have microscopically positive resection margins and/or pathologic locoregional nodal involvement (R1pN1) have a high-risk of locoregional recurrence, and therefore, we advocate the use of adjuvant chemoradiation. To evaluate the safety and effectiveness of this treatment, we compared survival and side effects outcomes between such patients and patients with negative resection margins and pathologically negative nodes (R0pN0) who did not receive adjuvant treatment. Methods Between 1984 and 2005, 65 patients were treated with curative-intended resection for extrahepatic bile duct adenocarcinoma. Patients with tumors arising in the gallbladder and periampullary region were excluded. Pathology and diagnostic images were centrally reviewed. Overall survival and locoregional recurrence outcomes for patients with standard-risk R0pN0 (surgery alone, or S group, n = 23) were compared with those of patients with high locoregional recurrence risk, R1 and/or pN1 (R1pN1) status who received adjuvant chemoradiation (S-CRT group, n = 42). Results The median follow-up for the entire group was 31 months. Patients in the S-CRT and S groups had a similar 5-year overall survival (36% vs. 42%, P = .6) and locoregional recurrence (5-year rate: 38% vs. 37%, P = .13). In the S-CRT group, three patients (7%) experienced an acute (grade 3 or more) side effect. Conclusions Our finding of a lack of a survival difference between the S and S-CRT groups suggests that for patients with extrahepatic bile duct adenocarcinoma at high risk for locoregional recurrence (i.e., R1 resection or pN1 disease), adjuvant chemoradiation provides an equivalent overall survival despite of these worse prognostic features. en_US
dc.language.iso en en_US
dc.title Extrahepatic Bile Duct Adenocarcinoma en_US
dc.type Article en_US
dc.description.version Published en_US
dc.title.subtitle Patients at High-Risk for Local Recurrence Treated with Surgery and Adjuvant Chemoradiation Have an Equivalent Overall Survival to Patients with Standard-Risk Treated with Surgery Alone en_US
dc.author.school SOM en_US
dc.author.idnumber 201100945 en_US
dc.author.woa N/A en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Gastrointestinal Oncology en_US
dc.journal.volume 15 en_US
dc.journal.issue 11 en_US
dc.article.pages 3147-3156 en_US
dc.identifier.doi http://dx.doi.org/10.1245/s10434-008-9998-7 en_US
dc.identifier.ctation Borghero, Y., Crane, C. H., Szklaruk, J., Oyarzo, M., Curley, S., Pisters, P. W., ... & Vauthey, J. N. (2008). Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Annals of surgical oncology, 15(11), 3147-3156. en_US
dc.author.email eddie.abdalla@lau.edu.lb
dc.identifier.url http://link.springer.com/article/10.1245/s10434-008-9998-7

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account